131i-tositumomab

The target site of 131I tositumomab is CD20, which can be used for the treatment of refractory non Hodgkin lymphoma.

Virtual price, please inquire if needed.

We can mass produce (kg level), process scaling up, pilot supply, raw material supply, and intermediate production. Our production technology is mature and more cost-effective. Feel free to inquire at any time.

msds of 131i-tositumomab